Purchase this article with an account.
Shelly R. Gupta, Jonathan S. Myers, Cristobal C. Cruz, Tania Tai, Sheryl S. Wizov, Marlene R. Moster, Michael J. Pro, Christopher J. Rapuano, John R. Wittpenn, L. J. Katz; Effects Of Latanoprost Versus Travoprost With Sofzia On The Ocular Surface Of Patients. Invest. Ophthalmol. Vis. Sci. 2011;52(14):229.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To quantify ocular surface changes in patients using latanoprost and travoprost with sofZia.
Prospective, single center, observational cohort study with masked examiner. Patients were classified into 2 groups. Group 1 was naïve to glaucoma therapy. Group 2 had been using latanoprost in both eyes for a least one month. Both groups were instructed to start (or continue) latanoprost in right eye, and to start travoprost with sofZia in left eye. At baseline, month 1, and month 2, measurements of tear break up time, corneal staining, conjunctival hyperemia, lissamine green vital staining, Schirmer testing of tear production, intraocular pressure, visual acuity, patient drug preference, and impression cytology with cellular typing were obtained. Ocular Surface Disease Index was used to measure patient comfort.
55 patients have been enrolled, 44 completed. Both Group 1 (n=26) and Group 2 (n=18) did not show any significant difference in tear break up time (p=0.60, 0.50), corneal staining (p=0.53, 1.00), conjunctival hyperemia (p=0.09, 0.51), lissamine green vital staining (p=0.93, 0.88), Schirmer testing (p=0.25, 0.13), intraocular pressure (p=0.64, 0.88), patient drug preference (p=0.86, 0.09), and impression cytology with cellular typing (p=0.16, 0.71). There were no significant differences between the eye receiving latanoprost or the eye receiving travoprost with sofZia for any outcome at any time. No significant differences were seen between Groups 1 and 2 with respect to treatment scores.
Our study did not demonstrate a significant difference in the ocular surface effects of patients using latanoprost with BAK versus travoprost with SofZia.
Clinical Trial: :
This PDF is available to Subscribers Only